Ebastine compared with placebo for diarrhea-predominant irritable bowel syndrome
Tests ebastine against placebo in adults with diarrhea-predominant irritable bowel syndrome.
Key facts
- Who runs it
- Md. Hazrat Ali
- Where
- Dhaka, BangladeshSee the site
- Trial code
- Registry title
- Effect of Ebastine in Patients With Diarrhea Predominant Irritable Bowel Syndrome
- Status
- Recruiting
- Phase
- Phase 2/3
- People taking part
- 60 people, planned
- Started
- 15 Aug 2025
- Planned end
- Jul 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- ebastine
- Placebo
- Record updated
- 20 August 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with irritable bowel syndrome where diarrhea is the main symptom (IBS-D). It compares ebastine with a placebo (dummy pill).
- Age
- 18 years and above
- Sex
- All sexes
- Disease stage
- IBS-D as defined by the Rome IV criteria.
- Earlier treatment
- People who had major surgery on the stomach or bowel cannot join.
Main reasons for not taking part
- Warning signs such as anemia, weight loss, bleeding from the rectum, needing the toilet at night, or family history of colon cancer
- Diseases that affect the digestive system, such as uncontrolled diabetes, hyperthyroidism or hypothyroidism
- Pregnant or breastfeeding women
- Vehicle drivers, machine operators and aerial operators
- Drug or alcohol abuse
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Age 18 and above
- Patients who meet the Rome IV criteria for IBS-D
Who cannot take part
- Drug abuse or alcohol abuse
- Presence of alarm features: anemia, weight loss, per rectal bleeding, nocturnal frequency, and family history of colonic cancer
- History of major gastrointestinal surgery
- Medical disease that affect the digestive system, such as uncontrolled diabetes, hyperthyroidism, hypothyroidism
- Pregnant and lactating women
- Vehicle drivers, mechanical operators and aerial operators
Where in Bangladesh
- Dhaka Medical CollegeDhaka, BangladeshContact: Md. Hazrat Ali, MBBSTaking people
About the trial
What the trial wants to find out
The goal of this clinical trial is to assess and compare the effect of ebastine and placebo in improving symptoms in patients with diarrhea predominant IBS. It will also assess about the safety of drugs ebastine and placebo by recording the patient reported adverse events. The main questions it aim to answer are:
Read full original descriptionShow less
Does drug ebastine and placebo has any effect on patients with IBS-D? What medical problems do participants have when taking drug ebastine and placebo? Researcher will compare effect of drug ebastine and placebo .
Participant will:
Take drug ebastine 20 mg at night and placebo once daily at night every day for 8 weeks along with lifestyle modifications. After that all two groups will visit the hospital 4 weekly, and their symptoms will be assessed by IBS symptom severity score (IBS-SSS) at baseline, week 4 and week 8. Additionally, patient reported adverse events will be documented.
The 2 groups in the trial
- EbastineExisting treatment, for comparison
Tab. Ebastine 20mg once daily at night
- PlaceboPlacebo, for comparison
Tab. Placebo once daily at night
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Effect of Ebastine in Patients With Diarrhea Predominant Irritable Bowel Syndrome
- Plain-language title
- Ebastine compared with placebo for diarrhea-predominant irritable bowel syndromeGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 20 August 2025